Slowly progressive type 1 diabetes treated with metformin for five years after onset

Takumi Hirata, Akira Shimada, Jiro Morimoto, Taro Maruyama

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

A 52-year-old man was diagnosed with slowly progressive type 1 diabetes (SPIDDM). We expected him to quickly progress to an insulin-dependent state due to a high anti-glutamic acid decarboxylase antibody titer (23.9 U/mL). At SPIDDM diagnosis, he was in a non-insulin-dependent state, with a fasting serum C-peptide immunoreactivity level of 2.5 ng/mL. Therefore, we prescribed metformin. His glycemic control remained stable, and his intrinsic insulin secretion capacity was maintained for five years. Although one case is insufficient to draw firm conclusions, this report suggests that metformin is a therapeutic choice for SPIDDM when the insulin secretion capacity is maintained.

Original languageEnglish
Pages (from-to)2635-2637
Number of pages3
JournalInternal Medicine
Volume52
Issue number23
DOIs
Publication statusPublished - 2013 Dec 5
Externally publishedYes

Keywords

  • Diabetes treatment
  • Metformin
  • Slowly progressive type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Slowly progressive type 1 diabetes treated with metformin for five years after onset'. Together they form a unique fingerprint.

Cite this